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 d   Institute of Pathology, University of Bern,  Bern , Switzerland 
(SNHL). Ulcerative colitis had been diagnosed 9 months previ-
ously (2006) and the patient was on oral prednisone (20 mg/day) 
and azathioprine (150 mg/day). Tapering prednisone had been 
tried several times without success as bowel symptoms worsened. 
Immunomodulatory therapy by infliximab was stopped because 
of side effects like itching, slight erythema on both upper arms 
due to scratching and maculopapulous partly pustular rash on the 
face, chest and back. No other side effects had been reported. Sub-
sequently certolizumab was initiated with no beneficial effect on 
the patient’s hearing capacity and no adverse events.
 His family medical history revealed neither autoimmune dis-
ease nor hearing loss. A normal ophthalmologic examination 
ruled out Cogan’s syndrome in differential diagnosis. In June 
2008 the patient developed aphthous lesions on the oral mucosa 
and granulomatous cheilitis. This and the finding of fistulas and 
abscesses of the colon led to a revision of the diagnosis to Crohn’s 
disease. 
 The first vertigo attack was noticed about 6 weeks and the first 
signs of hearing loss about 3 weeks before we saw the patient. 
Hearing loss first occurred on the right ear with tinnitus. The pa-
tient had been treated previously in a private practice outside 
Switzerland with antibiotics for otitis media, although there was 
no pain or feeling of pressure in the ear. An audiogram or other 
reports from this doctor were not available. The first audiogram 
in our clinic showed a bilateral SNHL of 50–55 dB at 0.125–2 kHz, 
90–100 dB at 3–8 kHz. On the left there was also SNHL of 20–35 
dB between 0.125 and 4 kHz and 45/35 dB at 6/8 kHz. At 12 kHz 
no tone was heard bilaterally. An MRI performed about half a year 
after the onset of symptoms showed a clear enhancement of con-
trast medium (gadolinium) in the left labyrinth. Four months lat-
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 Abstract 
 Patients with autoimmune inner ear disease develop rapidly 
progressive sensorineural hearing loss over a period of several 
weeks or months, often accompanied by vestibular loss. This 
disease can occur as a distinct clinical entity or in association 
with an underlying autoimmune disorder. Treatment compris-
es immunosuppression by corticosteroids, cytostatic drugs or 
tumor necrosis factor-  antagonists. We report histopatho-
logical and immunohistochemical findings of the inner ear of 
a patient with a granulomatous inner ear disease suffering 
from Crohn’s disease that was nonresponsive to treatment and 
who underwent surgery for bilateral cochlear implants. 
 Copyright © 2010 S. Karger AG, Basel 
 Case Report 
 A 27-year-old teacher was admitted to our ENT outpatient de-
partment because of repetitive attacks of rotary vertigo lasting 
about 1 day and repetitive sudden sensorineural hearing loss 
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er there was still significant contrast medium enhancement on 
the left and a possible enhancement in the semicircular canals on 
the right as well ( fig. 1 ).
 The pure-tone average at 0.5, 1 and 4 kHz was 26.25 dB on the 
left and 62.5 dB on the right ear. At that time the subjective vi-
sual vertical was tilted 2° to the left (pathological  1 2°) and the 
caloric response was only 2°/s with warm water (44  °  C) on the left 
and cold water (30   °   C) on the right. He had a right beating spon-
taneous nystagmus of 2°/s when looking to the right and complete 
visual suppression. There was also a head shaking nystagmus to 
the right of 3°/s. Smooth pursuit and saccades were normal. There 
were no other neurological symptoms or signs. Vestibular evoked 
myogenic potentials were reproducible on the right with clearly 
prolonged latencies (P 13 at 22.0 and 22.9 ms), but could not be 
evoked on the left, indicating a loss of saccular function on the left 
and a lesion, possibly in the vestibular nerve, on the left. Half a 
year later there was no spontaneous, gaze-evoked or head shaking 
nystagmus. Vestibular tests revealed complete bilateral loss: a ca-
loric nystagmus of 2° on cold water irrigation on the left and the 
head impulse test showed gain values for all semicircular canal 
planes between 0.06 and 0.25. Two transtympanic injections of 
about 0.5 ml dexamethasone (4 mg/ml) in both ears had a short, 
transient effect on hearing loss. Hearing was fluctuating with 
losses every 3–7 days. Four-tone pure-tone average increased 
from 62.5/26.25 dB (right/left) on August 28th 2008 to 113.7 dB 
on the right and complete deafness on the left on May 28th 2009.
 In summary, after having several episodes of sudden SNHL on 
both sides, the patient developed complete bilateral hearing and 
vestibular loss in less than 9 months. Summarizing clinical symp-
toms an autoimmune inner ear disease (AIED) was postulated.
 68-kD Western blot, previously used in AIED [Gottschlich et 
al., 1995; Moscicki et al., 1994], was not performed because sensi-
tivity and specificity are controversial. Laboratory tests revealed 
normal values for C-reactive protein on repeated analysis. Anti-
viral IgG antibodies against herpes simplex virus 1 and varicella 
zoster virus were positive with negative IgM, implying past infec-
tion. IgG against herpes simplex virus 2,  Borrelia burgdorferi and 
 Treponema pallidum were completely negative. Total serum IgG 
was borderline (16.2 g/l; normal value  ! 16.0 g/l). Antinuclear an-
tibodies and anti-native DNA antibodies were negative, whereas 
anti-neutrophil cytoplasmatic antibodies were positive at low titer 
(1: 40). Further specification showed neither classical reactivity to 
proteinase 3 nor atypical reactivity to myeloperoxidase.
 Furthermore, testing for antiphospholipid antibodies, anti-
cardiolipin and anti-  2 -glycoprotein 1 revealed negative results 
for all immunoglobulin classes as well as antimitochondrial and 
anti-smooth muscle antibodies. Lumbar puncture was also per-
formed with normal values for glucose, lactate and protein and
 ! 1 cell/  l.
 After oral and intratympanic treatment with dexamethasone 
had been unsuccessful, we started treatment with intravenous in-
fliximab (Remicade, 5 mg/kg). Although there was a slight im-
provement in gastrointestinal symptoms, there was no significant 
effect on hearing and an MRI showed persistent contrast medium 
enhancement in the labyrinths. As the above-mentioned adverse 
events occurred the regimen was changed to certolizimab (Cim-
zia, 400 mg subcutaneously), which caused no side effects but 
failed to improve or stabilize hearing. Finally the patient received 
cochlear implants (CIs), first on the left and 2 months later on the 
right side. There was some granulomatous tissue in the inner ear 
of the left side after opening of the round window which was re-
moved in order to insert the CI into the cochlea. This tissue was 
sent for histopathological and immunohistochemical analysis. 
Both CIs had an extremely fast and good effect on hearing and 
overall the patient was extremely well adapted. He even managed 
to go snowboarding with bilateral complete vestibular loss.
 Histopathologic and Immunopathologic Results 
 Immunohistochemical assays were performed according to 
standardized staining procedures using machines from Ventana 
and Medite and the following antibodies: CD3 (cloneSP7), CD163 
(163C01/10D6), NF-  B p65 (Rel A) purchased from NeoMarkers/
Lab Vision Corp. and CD68 (PG-M1), CD8 (C8/114B), CD20 
(L26), CD138 (MI 15), polyclonal anti-CD117 purchased from 
DAKO as well as CD4 (1F6) were purchased from Novocastra Lab. 
and polyclonal anti-HO-1 from StressGen Biotech. All antibodies 
were used according to the manufacturer’s recommendations 
[Dabbs, 2006].
 Conventional histology of inner ear tissue, stained with hema-
toxylin and eosin, showed mild chronic inflammation with the 
formation of granulomas ( fig. 2 ). The majority of the cellular con-
tents was identified as macrophages by immunohistochemical 
CD68 and CD163 reactivity ( fig. 3 ).
 Some CD3-positive T lymphocytes were also detected. Fur-
ther staining revealed some CD8-positive suppressor and cyto-
toxic T cells and negativity for helper/inducer T lymphocytes by 
CD4 staining ( fig. 4 ). Furthermore, very few CD20-positive ma-
ture B lymphocytes were detected, as well as a few CD138-positive 
plasma cells and very few CD117-positive mast cells. There was 
strong heme-oxygenase-1 (HO-1) expression ( fig.  5 ), which ex-
plains the inflammatory reaction, and strong positivity of the an-
ti-apoptotic nuclear transcription factor-  B (NF-  B) ( fig.  6 ), 
which mediates at least partly the HO-1 increase.
1 1
2
2
33
4
a
b
 Fig. 1. T 1 -weighted MRI with gadolinium showing slight gado-
linium enhancement in the vestibular nerve bilaterally (1) and in 
the left cochlea (2) ( a ), and in the left cochlea (2), the right hori-
zontal semicircular canal (3), and in the right vestibulum (4) ( b ). 
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 Discussion 
 AIED is a rare cause of SNHL first described in 1979 
[McCabe, 1979]. It is important to recognize this disease 
entity, because early diagnosis and proper management 
may prevent complete hearing loss. Unfortunately, there 
is no generally accepted serologic test available for the di-
agnosis of systemic autoimmune diseases [Dayal et al., 
2008].
 The pathogenesis of systemic autoimmune diseases re-
mains unclear but antibodies directed against the inner 
ear and/or cellular effectors have been proposed [Buniel et 
al., 2009; Harris and Sharp, 1990; Staecker and Lefe bvre, 
2002; Veldman, 1998]. Among the target antigens associ-
ated with progressive SNHL, type II collagens, type IX col-
lagens, 30-kD proteins of inner ear membranes, laminin, 
68-kD proteins of the inner ear, PO protein, Raf I protein 
and   -tubulin have been described [Yoo et al., 2002].
 Fig. 2. Mild chronic inflammation with formation of poorly de-
fined granulomas (arrow) and spindle cell macrophages (dashed 
arrow). Magnification  ! 100. 
 Fig. 3. CD68-positive macrophages are abundant (arrow) and are 
arranged in poorly formed granulomas (dashed arrow). Magnifi-
cation  ! 200. 
 Fig. 4. Some T lymphocytes, expressing CD8 (arrows). Magnifica-
tion  ! 200. 
 Fig. 5. Strong HO-1 expression in activated macrophages (ar-
rows). Magnification  ! 200. 
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 Autoimmune reactivity to the inner ear has been ob-
served as a clinical feature in various systemic immune-
mediated disorders, such as Cogan’s syndrome, Behçet’s 
disease, Wegener’s granulomatosis, systemic sclerosis, 
systemic lupus erythematosus, giant cell arteritis, panar-
teritis nodosa and unclassified systemic vasculitis [Stone 
and Francis, 2000]. Not surprising, it has also been linked 
to inflammatory bowel disease [Harris and Sharp, 1990; 
Karmody et al., 2009; Staecker and Lefebvre, 2002]. In an 
animal model [Harris, 1987] and a histopathological 
study of the temporal bones in 1 patient with ulcerative 
colitis, lymphocytic infiltration of the inner ear was 
found [Hoistad et al., 1998], which is different from our 
findings but also suggests an autoimmune process. Even 
an immunohistopathological study does not necessarily 
imply that the hearing loss is a manifestation of AIED.
 As a distinct clinical entity without other immune-
mediated disorders, it was termed AIED, but nowadays 
this term is also used if a typical inner ear disease is cou-
pled with other autoimmune diseases. Being associated 
with so many different systemic disorders, it is not sur-
prising that the clinical course is extremely variable. This 
may also reflect different activation stages of differing 
underlying autoimmune disorders.
 In contrast, if AIED is not associated with another au-
toimmune disorder, it is usually characterized by rapidly 
developing (weeks or months) and progressive hearing 
loss [Berrettini et al., 1998].
 Typically AIED is first treated with high-dose cortico-
steroids [Buniel et al., 2009; Dayal et al., 2008; Harris et 
al., 2003]. If this treatment is insufficient, other drugs like 
methotrexate may be administered, although in some pa-
tients the disease still progresses [Salley et al., 2001]. A 
newer promising treatment option is the administration 
of a tumor necrosis factor-  (TNF-  ) blocker like inflix-
imab [Staecker and Lefebvre, 2002; Van Wijk et al., 2006]. 
Since the administration of different medications had no 
effect in our patient, CIs were applied. We were able to 
examine some tissue from the patient’s inner ear which 
was removed when the cochlear electrodes were implant-
ed. The tissue studied was in direct contact with the 
round window membrane and behind it. Histology re-
vealed tissue with poorly formed granulomas and abun-
dant activated macrophages positive for CD68 and CD163 
and strongly expressing HO-1. Besides that, there was an 
infiltrate of mononuclear cells with a strong activation of 
NF-  B. As our patient suffered from Crohn’s disease, it is 
possible that the granulomas we found in his inner ear 
were associated with this autoimmune disorder, since 
they are one of the histological hallmarks of Crohn’s dis-
ease. On the other hand, sarcoid-like granulomatous re-
actions are rare but not exceptional in patients treated 
with TNF blockers (approximately 1/2800) and do not 
seem to be related to gender, rheumatic disease or type of 
anti-TNF drug used. As described, they resolve after dis-
continuation [Daien et al., 2009]. We could not exclude 
an effect of the TNF-blocking agents in this study.
 There is evidence that HO-1 is also involved in this 
complex autoimmune process in inflammatory bowel 
disease  and provides endogenous antioxidant and anti-
inflammatory moieties that can modulate colonic in-
flammation [Horvath et al., 2008; Paul et al., 2005]. 
 The effector immune cells produce high levels of pro-
inflammatory cytokines in inflammatory bowel disease 
and the NF-  B pathway was identified as one of the key 
factors in inflammatory bowel disease [Atreya et al., 
2008; Ellis et al., 1998].
 Crohn’s disease is considered a systemic immunopa-
thy that has many well-documented extraintestinal man-
ifestations like joints, eyes or other regions of the head 
like the larynx, oral cavity and the nose [Aloi and Cuc-
chiara, 2009; Bradley et al., 2004; Lakatos et al., 2003].
 The findings described here resemble the histopatho-
logical characteristics of Crohn’s disease. Therefore, we 
suggest that our patient did not have classic AIED but 
might have suffered from an extraintestinal manifesta-
tion of Crohn’s disease. As in Crohn’s disease, not all pa-
tients can be successfully treated with standard immuno-
 Fig. 6. Strong activation of the antiapoptotic NF-  B (arrows). 
Magnification  ! 200. 
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suppression, and some patients with AIED may require 
the new TNF-  blockers for beneficial treatment [Rut-
geerts et al., 2009; Staecker and Lefebvre, 2002; Van Wijk 
et al., 2006]. As some patients like ours may still not re-
spond to therapy, there is a need for new treatment op-
tions and better characterization of the underlying auto-
immune process.
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